Marsh McLennan (MRSH)
NYSEFinancialsInsurance - BrokersSnapshot 2026-09-04
$185.74-1.44%
Close 2026-09-04 · 1-day change
NYSEFinancialsInsurance - BrokersSnapshot 2026-09-04
Intact: The reason to own it still holds.
Marsh McLennan grows revenue about 10% in 2026. Adjusted EPS rises 8% to $3.29. The company has stable profit margins and a strong market position. Free cash flow yield is solid at 6%.
Revenue growth could slow below 6% if demand weakens. Profit margins may compress due to cost pressures. Debt from new credit agreements could limit financial flexibility.
The market prices in about 5.5% revenue growth and values the stock roughly 15% above our fair value near $155. Our fair value is below the Street median, reflecting cautious optimism on growth and margins.
Breaks if: adjusted EPS growth falls below 5% in FY26
Breaks if: Leverage or liquidity deteriorates materially beyond historical norms
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a durable compounder investment with a focus on maintaining strong financial performance. The current thesis state is intact, supported by recent strong results, but it is priced at a premium compared to peers.
The market currently assumes a durable premium for MRSH, reflecting its strong recent performance but also its fragile earnings quality. The expectations gap is slightly negative, indicating that while the company is performing well, there is some skepticism about its future execution.
Fundamentals are likely to remain strong in the near term, as management has consistently prioritized earnings growth and capital allocation. However, there is a moderate risk due to the potential for guidance cuts, which could impact sentiment.
The long-term thesis hinges on the performance of sector bellwethers like AON, AJG, and WTW. If these companies continue to perform well, MRSH could benefit from the positive momentum in the Financials sector.
The most important moves since the prior daily snapshot.
Signal changed from 'mild_favorable' to 'mixed'.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats to the thesis at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: No progress or setbacks in Thrive program efficiency gains by FY26
Breaks if: YoY revenue growth falls below 6% in FY26
Overall, MRSH's strong financial performance and sector support provide a solid foundation, but its premium valuation and potential risks require careful monitoring. Not investment advice.